Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Vail

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Opinion in Ophthalmology|June 24, 2006
Diabetic vitrectomy: risks, prognosis, future trendsJohn O Mason, Cheri T Colagross, Rachel Vail
Retinal Cases & Brief Reports|November 13, 2014
Scleral buckle removal as treatment for persistent subfoveal fluid after scleral buckle surgery for retinal detachmentJohn O Mason, Alinda A McGowin, Rachel Vail
Retina (Philadelphia, Pa.)|August 1, 2008
Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathyJohn O Mason, Jacob J Yunker, Rachel Vail, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Opinion in Ophthalmology|June 24, 2006
Diabetic vitrectomy: risks, prognosis, future trendsJohn O Mason, Cheri T Colagross, Rachel Vail
Retinal Cases & Brief Reports|November 13, 2014
Scleral buckle removal as treatment for persistent subfoveal fluid after scleral buckle surgery for retinal detachmentJohn O Mason, Alinda A McGowin, Rachel Vail
Retina (Philadelphia, Pa.)|August 1, 2008
Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathyJohn O Mason, Jacob J Yunker, Rachel Vail, et al.
Pageof 1